Innoviva (INVA) Innoviva, Inc. Presents at UBS Global Healthcare Conference 2024 summary

Company overview and strategy

• Focuses on maximizing value from royalty streams, now diversifying into high-growth therapeutics and strategic healthcare investments.

• Royalty portfolio from respiratory drugs expected to generate $1.25 billion over five years, with $200 million annually and minimal costs.

• Capital allocation targets high unmet medical needs and long-term shareholder value.

• Three main assets: royalty portfolio, critical care/infectious disease therapeutics (IST), and a $500M+ healthcare investment portfolio.

• Royalty streams are resilient, with global growth and strong IP protection.

Critical care and infectious disease therapeutics (IST)

• IST platform generated $100M+ in sales and license revenue in the last 12 months, doubling year over year.

• Built on differentiated products with strong synergies and novel mechanisms for severe infections and septic shock.

• Key products: Giapreza (shock), Xacduro (carbapenem-resistant Acinetobacter), Xerava (broad-spectrum antibiotic), and zoliflodacin (resistant gonorrhea, pre-NDA).

• All products have patent protection into the mid- to late 2030s, supporting revenue durability.

• IST is positioned for further organic and inorganic growth, aiming for standalone profitability within a year.

Product highlights and growth drivers

• Giapreza restores blood pressure in shock patients unresponsive to other therapies; guideline inclusion and new data are key growth drivers.

• Xacduro addresses a critical unmet need for carbapenem-resistant infections, with targeted use improving access and stewardship.

• Xerava offers broad-spectrum coverage and is positioned as a carbapenem-sparing therapy with better tolerability.

• Zoliflodacin met phase III endpoints for resistant gonorrhea, offering an oral alternative and addressing a growing global need.

• Xacduro and Xerava received preferred guideline placement; Xacduro approved in China, earning $14M in milestone payments.